TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04430413

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
Study: NCT03612427

Intervention type: DIETARY_SUPPLEMENT
Intervention: S. Cholesterol S. Triglyceride
Description: S. Cholesterol S. Triglycerides

Intervention type: DIETARY_SUPPLEMENT
Intervention: S. Cholesterol S. Triglyceride
Description: S. Cholesterol S. Triglycerides
Study: NCT00985621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 10 mg
Description: tanezumab 10 mg one dose at weeks 0 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 5 mg
Description: tanezumab 5 mg one dose at weeks 0 and 8
Study: NCT00773058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: hydrocortisone 100mg q8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: hydrocortisone 100mg q8h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline 100ml q8h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline 100ml q8h
Study: NCT00985621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: oxycodone CR, 10-40 mg q12h

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00316589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
Study: NCT01108484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise: Three 90-minutes sessions per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet counseling
Description: Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet counseling + psycho-emotional support
Description: Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
Study: NCT01554371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02409121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education information system
Description: Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
Study: NCT05013866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair resin composite proximal
Description: Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair resin composite proximal
Description: Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
Study: NCT04501133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation
Description: Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation
Description: Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single pulse TMS
Description: Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single pulse TMS
Description: Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
Study: NCT02344537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga
Description: Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
Study: NCT01031472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 formulation 1
Description: 100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 reference formulation
Description: GSK2248761 100mg Gelucire reference capsule with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 formulation 3
Description: 100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 formulation 2 or 4
Description: 100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
Study: NCT03274154

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Hyaluron 465 Innēov
Description: Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
Study: NCT00416260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequency Oscillation and Tracheal Gas Insufflation
Description: Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
Study: NCT01633216

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent OPV 2 week interval
Description: Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent OPV 4 week interval
Description: Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent OPV 2 week interval
Description: Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent OPV 4 week interval
Description: Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent OPV 4 week interval
Description: Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
Study: NCT00402337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide acetate
Description: oral, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide acetate
Description: oral, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide acetate
Description: oral, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide acetate
Description: oral, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: oral, once daily
Study: NCT03555357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
Study: NCT04133259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody
Description: Treatment of CHB patient with HLX10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside/nucleotide analogues
Description: Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: pregabaline
Description: titration

Intervention type: BIOLOGICAL
Intervention: pregabaline
Description: titration
Study: NCT01946529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: If participant meets the criteria, they will have surgical resection of their tumor.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
Study: NCT04963998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Wound Dressings with Copper Oxide
Description: Application of Wound Dressings with Copper Oxide on chronic foot wounds in diabetic patients
Study: NCT01766323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: sultiame
Description: titration

Intervention type: BIOLOGICAL
Intervention: sultiame
Description: titration
Study: NCT05051683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer
Description: endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
Study: NCT04758156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CleanViewAL
Description: 1L PEG + ascorbic acid bowel preparation for colonoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUPREP
Description: Oral sulfate solution for colonoscopy bowel preparation
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: tiagabine
Description: titration

Intervention type: BIOLOGICAL
Intervention: tiagabine
Description: titration

Intervention type: BIOLOGICAL
Intervention: vigabatrine
Description: titration

Intervention type: BIOLOGICAL
Intervention: vigabatrine
Description: titration

Intervention type: BIOLOGICAL
Intervention: mesuximide
Description: titration

Intervention type: BIOLOGICAL
Intervention: mesuximide
Description: titration

Intervention type: BIOLOGICAL
Intervention: primidone
Description: titration

Intervention type: BIOLOGICAL
Intervention: primidone
Description: titration

Intervention type: BIOLOGICAL
Intervention: perampanel
Description: titration
Study: NCT03904888

Intervention type: PROCEDURE
Group type: OTHER
Intervention: r-TAPP
Description: Robot-assisted repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: r-TAPP
Description: Robot-assisted repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: l-TAPP
Description: Laporoscopic repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: l-TAPP
Description: Laporoscopic repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: local anesthetics
Description: local anesthetics will be administred
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: perampanel
Description: titration

Intervention type: BIOLOGICAL
Intervention: ethosuximide
Description: titration

Intervention type: BIOLOGICAL
Intervention: ethosuximide
Description: titration

Intervention type: BIOLOGICAL
Intervention: zonisamide
Description: titration

Intervention type: BIOLOGICAL
Intervention: zonisamide
Description: titration

Intervention type: BIOLOGICAL
Intervention: cannabidiol
Description: titration

Intervention type: BIOLOGICAL
Intervention: cannabidiol
Description: titration

Intervention type: OTHER
Intervention: genetic polymorphisms
Description: genetic polymorphisms
Study: NCT00611663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar® and Pneumo23®
Description: Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Pneumo23®
Description: Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
Study: NCT03909919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care or Usual Clinical Practice
Description: The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Care or Usual Clinical Practice
Description: The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
Study: NCT01582633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2012 trivalent influenza vaccine
Description: 2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2012 trivalent influenza vaccine
Description: 2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2012 trivalent influenza vaccine
Description: 2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2012 trivalent influenza vaccine
Description: 2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose.
Study: NCT04529252

Intervention type: OTHER
Intervention: Specimen collection
Description: Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected

Intervention type: OTHER
Intervention: Specimen collection
Description: Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
Study: NCT03991169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight \>43 kg.
Study: NCT03973918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450mg QD 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450mg QD 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450mg QD 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450mg QD 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45mg BID 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45mg BID 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45mg BID 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45mg BID 28 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Research Bloods
Description: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Research Bloods
Description: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Research Bloods
Description: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Research Bloods
Description: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Tissue
Description: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Tissue
Description: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Tissue
Description: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Tissue
Description: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
Study: NCT01996865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study: NCT04088071

Intervention type: DEVICE
Intervention: Catheter ablation
Description: Ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
Study: NCT02926586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
Study: NCT06622447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: βGluCnCs intervention
Description: The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into βGluCnCs intervention (N=40).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into placebo intervention (N=20).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks.
Study: NCT03904888

Intervention type: PROCEDURE
Group type: OTHER
Intervention: local anesthetics
Description: local anesthetics will be administred
Study: NCT01138137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles